STML has been the topic of a number of other research reports. Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a report on Sunday, August 4th. BidaskClub downgraded Stemline Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Wedbush upgraded Stemline Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Friday, August 2nd. HC Wainwright set a $35.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 20th. Finally, Roth Capital reiterated a “buy” rating on shares of Stemline Therapeutics in a research note on Thursday, May 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. Stemline Therapeutics currently has a consensus rating of “Buy” and an average price target of $23.50.
STML traded down $0.08 during mid-day trading on Wednesday, reaching $11.19. 477,947 shares of the company traded hands, compared to its average volume of 607,681. The stock has a market capitalization of $509.06 million, a P/E ratio of -3.74 and a beta of 1.39. The company has a quick ratio of 4.57, a current ratio of 4.71 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average price is $13.47 and its 200-day moving average price is $13.74. Stemline Therapeutics has a 52-week low of $7.82 and a 52-week high of $18.22.
Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Friday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.05. The firm had revenue of $13.01 million during the quarter, compared to analysts’ expectations of $8.84 million. As a group, sell-side analysts forecast that Stemline Therapeutics will post -1.98 earnings per share for the current fiscal year.
In related news, COO Kenneth Hoberman sold 47,115 shares of Stemline Therapeutics stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $15.07, for a total transaction of $710,023.05. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Ivan Bergstein sold 56,316 shares of the business’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $15.08, for a total value of $849,245.28. The disclosure for this sale can be found here. Insiders sold a total of 158,370 shares of company stock valued at $2,383,666 over the last 90 days. 13.10% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of STML. BNP Paribas Arbitrage SA purchased a new position in shares of Stemline Therapeutics during the 1st quarter valued at about $102,000. Knott David M raised its stake in Stemline Therapeutics by 1.3% during the 1st quarter. Knott David M now owns 157,795 shares of the biopharmaceutical company’s stock worth $2,028,000 after acquiring an additional 2,000 shares during the period. Bank of America Corp DE lifted its holdings in Stemline Therapeutics by 56.8% during the fourth quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 3,866 shares in the last quarter. Rhenman & Partners Asset Management AB purchased a new position in Stemline Therapeutics during the second quarter valued at approximately $7,568,000. Finally, Candriam Luxembourg S.C.A. bought a new position in shares of Stemline Therapeutics in the second quarter worth approximately $1,220,000. Institutional investors and hedge funds own 82.46% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Featured Story: Resistance Level
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.